Homocysteine and Gliotoxicity.
Angela T S WyseLarissa Daniele BoberminTiago Marcon Dos SantosAndré Quincozes-SantosPublished in: Neurotoxicity research (2021)
Homocysteine is a sulfur amino acid that does not occur in the diet, but it is an essential intermediate in normal mammalian metabolism of methionine. Hyperhomocysteinemia results from dietary intakes of Met, folate, and vitamin B12 and lifestyle or from the deficiency of specific enzymes, leading to tissue accumulation of this amino acid and/or its metabolites. Severe hyperhomocysteinemic patients can present neurological symptoms and structural brain abnormalities, of which the pathogenesis is poorly understood. Moreover, a possible link between homocysteine (mild hyperhomocysteinemia) and neurodegenerative/neuropsychiatric disorders has been suggested. In recent years, increasing evidence has emerged suggesting that astrocyte dysfunction is involved in the neurotoxicity of homocysteine and possibly associated with the physiopathology of hyperhomocysteinemia. This review addresses some of the findings obtained from in vivo and in vitro experimental models, indicating high homocysteine levels as an important neurotoxin determinant of the neuropathophysiology of brain damage. Recent data show that this amino acid impairs glutamate uptake, redox/mitochondrial homeostasis, inflammatory response, and cell signaling pathways. Therefore, the discussion of this review focuses on homocysteine-induced gliotoxicity, and its impacts in the brain functions. Through understanding the Hcy-induced gliotoxicity, novel preventive/therapeutic strategies might emerge for these diseases.
Keyphrases
- amino acid
- inflammatory response
- oxidative stress
- resting state
- end stage renal disease
- white matter
- diabetic rats
- high glucose
- physical activity
- signaling pathway
- newly diagnosed
- cerebral ischemia
- metabolic syndrome
- drug induced
- weight loss
- cardiovascular disease
- chronic kidney disease
- single cell
- functional connectivity
- stem cells
- early onset
- type diabetes
- peritoneal dialysis
- electronic health record
- patient reported outcomes
- tyrosine kinase
- endothelial cells
- big data
- cell therapy
- depressive symptoms
- artificial intelligence
- blood brain barrier
- epithelial mesenchymal transition
- lps induced
- subarachnoid hemorrhage
- deep learning
- replacement therapy